THINK Retirement NOW. ™

Most people think of dementia starting in a person’s 70s, 80s, and 90s, but research shows that the groundwork is laid as people enter their 40s, 50s, and 60s.  That's the bad news. The Good news:  Science now has concluded how to delay or reduce the symptoms of dementia and alzheimers, step by step (and its not just doing crossword puzzles!!)   We’ll have the intriguing Wall Street Journal report in the Market Intel segment, and then get into spousal income planning in Segment 3.  MASTERING MONEY is on the air!!!!

Daily IQ Retirement Brief 4/9/24

Bidenomics! Inflation! China! Digital currency! And, an upcoming Presidential election--a lot is happening in the world these days and it could affect your investments. Who better to comment on timely issues than the great Lou Dobbs? Today, Lou is our special guest host for segments 2 and 3, with commentary from Steve in segments 1 and 4.  This is a great podcast you don't want to miss...MASTERING MONEY is on the air!!

Daily IQ Retirement Brief 4/8/24

Although the market is taking a bit of a breather right now, several prominent traders are pointing to a technical sentiment signal with a 100% success rate over the past five decades, which is suddenly flashing a green light. That report in the Market Intel segment, then Shelley Grandidge joins us to give us guidance on the best health insurance opportunities. A fact filled show...MASTERING MONEY is on the air!!!

Daily IQ Retirement Brief 4/5/24

A small set of companies that own nuclear reactors have seen their stocks soar at Nvidia-like rates in the past few months, says Barrons--part of a little-noticed renaissance in an industry that hasn’t had much to brag about in years. We'll review that report in the Market Intel segment. Then we’ll examine recent studies on how much it takes to retire comfortably today (hint: about $1.47 million) A great show for you today, MASTERING MONEY is on the air!!!

Daily IQ Retirement Brief 4/4/24

Two of the hottest healthcare pharmaceutical stocks in the past two years have been Eli Lilly Company and NovoNordisk, the two makers of the most popular approved weight loss drugs.  But do the drugs work for everybody?  No, we'll tell you who the drugs do NOT work for in the Market Intel segment per the Wall Street Journal,  then Shelley Grandidge joins us review today's best health insurance options.  MASTERING MONEY  is on the air!!

Daily IQ Retirement Brief 4/3/24